{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:29:46Z","timestamp":1777613386561,"version":"3.51.4"},"reference-count":24,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T00:00:00Z","timestamp":1613865600000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,2,8]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Sarcoidosis is a multisystem inflammatory disorder of uncertain aetiology. There are numerous case reports of sarcoidosis occurring during treatment with biological immunotherapies. Here, we describe the case of a 52-year-old woman with psoriatic arthritis who developed multisystem sarcoidosis while being treated with secukinumab (anti-interleukin-17A) therapy which, to our knowledge, is the first such case. We discuss existing literature and hypothesise that IL-17 blockade may precipitate the development of granulomatous disease.<\/jats:p>","DOI":"10.1136\/bcr-2020-240615","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:36:14Z","timestamp":1613993774000},"page":"e240615","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-6721","authenticated-orcid":false,"given":"Colm","family":"Kirby","sequence":"first","affiliation":[{"name":"Rheumatology, Tallaght University Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darragh","family":"Herlihy","sequence":"additional","affiliation":[{"name":"Radiology, Beaumont Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Clarke","sequence":"additional","affiliation":[{"name":"Pathology, Tallaght University Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Mullan","sequence":"additional","affiliation":[{"name":"Rheumatology, Tallaght University Hospital, Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"2025082711592776000_14.2.e240615.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.04.015","article-title":"Natalizumab induced cutaneous sarcoidosis-like reaction","volume":"333","author":"Durcan","year":"2019","journal-title":"J Neuroimmunol"},{"key":"2025082711592776000_14.2.e240615.2","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1111\/1346-8138.14887","article-title":"Sarcoid-like reaction and vitiligo occurring after nivolumab therapy in a patient with metastatic melanoma","volume":"46","author":"Fukuchi","year":"2019","journal-title":"J Dermatol"},{"key":"2025082711592776000_14.2.e240615.3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/RLU.0000000000002408","article-title":"Fdg PET\/CT course of Pembrolizumab-Associated multiorgan sarcoidosis","volume":"44","author":"Lu","year":"2019","journal-title":"Clin Nucl Med"},{"key":"2025082711592776000_14.2.e240615.4","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir"},{"key":"2025082711592776000_14.2.e240615.5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00105-018-4186-6","article-title":"Sarcoidosis triggered by immune checkpoint blockade]","volume":"69","author":"Heppt","year":"2018","journal-title":"Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete"},{"key":"2025082711592776000_14.2.e240615.6","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1111\/1346-8138.14268","article-title":"Cutaneous sarcoidosis in a patient with rheumatoid arthritis receiving tocilizumab","volume":"45","author":"Shono","year":"2018","journal-title":"J Dermatol"},{"key":"2025082711592776000_14.2.e240615.7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1684\/ejd.2017.3143","article-title":"Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect?","volume":"27","author":"Pescitelli","year":"2017","journal-title":"European Journal of Dermatology"},{"key":"2025082711592776000_14.2.e240615.8","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/bjd.13365","article-title":"Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis","volume":"172","author":"Powell","year":"2015","journal-title":"British Journal of Dermatology"},{"key":"2025082711592776000_14.2.e240615.9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1155\/2015\/265734","article-title":"Cutaneous sarcoidosis in a patient with severe asthma treated with omalizumab","volume":"22","author":"Yung","year":"2015","journal-title":"Canadian Respiratory Journal"},{"key":"2025082711592776000_14.2.e240615.10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.rmed.2019.01.015","article-title":"The development of sarcoidosis in patients receiving daclizumab: a case series from multiple clinical trials","volume":"149","author":"Judson","year":"2019","journal-title":"Respir Med"},{"key":"2025082711592776000_14.2.e240615.11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/1352458518790391","article-title":"Sarcoidosis following alemtuzumab treatment for multiple sclerosis","volume":"24","author":"Willis","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"key":"2025082711592776000_14.2.e240615.12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14728220903449244","article-title":"Targeting the TNF-\u03b1 pathway in sarcoidosis","volume":"14","author":"Antoniu","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"2025082711592776000_14.2.e240615.13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.amjcard.2019.07.067","article-title":"Infliximab for refractory cardiac sarcoidosis","volume":"124","author":"Harper","year":"2019","journal-title":"Am J Cardiol"},{"key":"2025082711592776000_14.2.e240615.14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.149989"},{"key":"2025082711592776000_14.2.e240615.15","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/hep.28966","article-title":"Anti-TNF-\u03b1 for necrotizing sarcoid granulomatosis of the liver","volume":"65","author":"Sebode","year":"2017","journal-title":"Hepatology"},{"key":"2025082711592776000_14.2.e240615.16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09546634.2017.1329511","article-title":"Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease","volume":"29","author":"Hohenberger","year":"2018","journal-title":"Journal of Dermatological Treatment"},{"key":"2025082711592776000_14.2.e240615.17","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200001000-00012"},{"key":"2025082711592776000_14.2.e240615.18","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4049\/jimmunol.157.2.910","article-title":"Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis","volume":"157","author":"Agostini","year":"1996","journal-title":"Journal of immunology"},{"key":"2025082711592776000_14.2.e240615.19","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.1.7599865"},{"key":"2025082711592776000_14.2.e240615.20","doi-asserted-by":"publisher","DOI":"10.1002\/path.1508"},{"key":"2025082711592776000_14.2.e240615.21","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000301"},{"key":"2025082711592776000_14.2.e240615.22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4049\/jimmunol.166.1.642","article-title":"Il-12 and IL-18 are increased and stimulate IFN-\u03b3 production in sarcoid lungs","volume":"166","author":"Shigehara","year":"2001","journal-title":"The Journal of Immunology"},{"key":"2025082711592776000_14.2.e240615.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker316"},{"key":"2025082711592776000_14.2.e240615.24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ced.14101","article-title":"Management with secukinumab of tumour necrosis factor inhibitor\u2010induced pulmonary sarcoidosis\u2010like reaction in a patient with psoriasis","volume":"45","author":"Eichhoff","year":"2020","journal-title":"Clin Exp Dermatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-240615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:59:37Z","timestamp":1756321177000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-240615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,22]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bcr-2020-240615"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-240615","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}